iBio, Inc. Statistics
Total Valuation
iBio, Inc. has a market cap or net worth of $7.41 million. The enterprise value is $5.05 million.
Important Dates
The next estimated earnings date is Monday, May 12, 2025, after market close.
| Earnings Date | May 12, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
iBio, Inc. has 9.87 million shares outstanding. The number of shares has increased by 557.78% in one year.
| Current Share Class | 9.87M |
| Shares Outstanding | 9.87M |
| Shares Change (YoY) | +557.78% |
| Shares Change (QoQ) | +5.78% |
| Owned by Insiders (%) | 4.35% |
| Owned by Institutions (%) | 20.58% |
| Float | 8.60M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 14.02 |
| Forward PS | 35.83 |
| PB Ratio | 0.46 |
| P/TBV Ratio | 0.94 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 13.46 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 1.76, with a Debt / Equity ratio of 0.34.
| Current Ratio | 1.76 |
| Quick Ratio | 1.49 |
| Debt / Equity | 0.34 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -68.85 |
Financial Efficiency
Return on equity (ROE) is -123.28% and return on invested capital (ROIC) is -43.11%.
| Return on Equity (ROE) | -123.28% |
| Return on Assets (ROA) | -34.91% |
| Return on Invested Capital (ROIC) | -43.11% |
| Return on Capital Employed (ROCE) | -91.59% |
| Revenue Per Employee | $23,438 |
| Profits Per Employee | -$1.21M |
| Employee Count | 16 |
| Asset Turnover | 0.01 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -57.87% in the last 52 weeks. The beta is 1.02, so iBio, Inc.'s price volatility has been similar to the market average.
| Beta (5Y) | 1.02 |
| 52-Week Price Change | -57.87% |
| 50-Day Moving Average | 3.69 |
| 200-Day Moving Average | 2.72 |
| Relative Strength Index (RSI) | 19.10 |
| Average Volume (20 Days) | 1,191,297 |
Short Selling Information
The latest short interest is 1.17 million, so 11.87% of the outstanding shares have been sold short.
| Short Interest | 1.17M |
| Short Previous Month | 454,207 |
| Short % of Shares Out | 11.87% |
| Short % of Float | 13.63% |
| Short Ratio (days to cover) | 1.81 |
Income Statement
In the last 12 months, iBio, Inc. had revenue of $375,000 and -$19.30 million in losses. Loss per share was -$2.57.
| Revenue | 375,000 |
| Gross Profit | 375,000 |
| Operating Income | -15.56M |
| Pretax Income | n/a |
| Net Income | -19.30M |
| EBITDA | -14.71M |
| EBIT | -15.56M |
| Loss Per Share | -$2.57 |
Full Income StatementBalance Sheet
The company has $7.02 million in cash and $4.75 million in debt, giving a net cash position of $2.26 million or $0.23 per share.
| Cash & Cash Equivalents | 7.02M |
| Total Debt | 4.75M |
| Net Cash | 2.26M |
| Net Cash Per Share | $0.23 |
| Equity (Book Value) | 13.90M |
| Book Value Per Share | 1.52 |
| Working Capital | 3.58M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$16.09 million and capital expenditures -$211,000, giving a free cash flow of -$16.30 million.
| Operating Cash Flow | -16.09M |
| Capital Expenditures | -211,000 |
| Free Cash Flow | -16.30M |
| FCF Per Share | -$1.65 |
Full Cash Flow StatementMargins
| Gross Margin | 100.00% |
| Operating Margin | -4,149.33% |
| Pretax Margin | -3,795.73% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
iBio, Inc. does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -557.78% |
| Shareholder Yield | -557.78% |
| Earnings Yield | -264.09% |
| FCF Yield | -223.05% |
Analyst Forecast
The average price target for iBio, Inc. is $4.87, which is 549.33% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $4.87 |
| Price Target Difference | 549.33% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 3 |
| Revenue Growth Forecast (5Y) | n/a |
| EPS Growth Forecast (5Y) | -34.64% |
Stock ForecastsStock Splits
The last stock split was on November 29, 2023. It was a reverse split with a ratio of 0.05:1.
| Last Split Date | Nov 29, 2023 |
| Split Type | Reverse |
| Split Ratio | 0.05:1 |
Scores
iBio, Inc. has an Altman Z-Score of -21.77 and a Piotroski F-Score of 3. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -21.77 |
| Piotroski F-Score | 3 |